Replies to post #192421 on Biotech Values

[DewDiligence]

ABBV—Good thing they bought Imbruvica so that they don't have to compete against it (at least in the US).

Indeed. ABBV surely will not try to compete against Imbruvica in any geography insofar as Imbruvica’s worldwide profits are split 50/50 between ABBV and JNJ.